STOCK TITAN

NovAccess Global Advisory on Annual Meeting of Shareholders

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

NovAccess Global Inc. (XSNX) has postponed its Annual Meeting of Shareholders scheduled for May 2024. The company plans to reschedule the meeting soon after announcing a virtual meeting for shareholders on May 6th, 2024.

Positive
  • None.
Negative
  • None.

CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company expects to reschedule the annual meeting shortly.

The Company previously announced that it would be hosting a virtual annual meeting of shareholders on May 6th, 2024 for shareholders of record as of April 1, 2024.

About NovAccess Global

NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

Follow us on social media and stay up to date on all of our developments:

https://www.youtube.com/@novaccess

https://www.facebook.com/novaccessglobal

https://www.linkedin.com/company/64892686

https://twitter.com/novaccessglobal

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Investor Relations Contact:

Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com

SOURCE: NovAccess Global Inc.



View the original press release on accesswire.com

FAQ

When was NovAccess Global Inc.'s Annual Meeting of Shareholders postponed?

NovAccess Global Inc. (XSNX) postponed its Annual Meeting of Shareholders scheduled for May 2024.

What type of company is NovAccess Global Inc.?

NovAccess Global Inc. is a biomedical company that develops novel immunotherapies for brain tumor patients.

When was the virtual annual meeting of shareholders supposed to take place?

The virtual annual meeting of shareholders was scheduled for May 6th, 2024.

What is NovAccess Global Inc.'s stock symbol?

NovAccess Global Inc.'s stock symbol is XSNX.

When was the previous announcement made regarding the annual meeting?

The previous announcement was made on April 1, 2024, for shareholders of record.

What is NovAccess Global Inc.'s plan regarding the rescheduling of the annual meeting?

The company expects to reschedule the annual meeting shortly after the postponement.

NOVACCESS GLOBAL INC

OTC:XSNX

XSNX Rankings

XSNX Latest News

XSNX Stock Data

619.07k
29.08M
49.89%
3.14%
Biotechnology
Healthcare
Link
United States of America
Chagrin Falls